Life Science Washington and Product Creation Studio present: DeviceConnect Series

Network and learn from innovators like you.

EVENT DESCRIPTION: BRINGING HEALTHCARE INTO THE HOME

The global smart home healthcare market is exploding as more medical devices are designed for use wherever the patient is, including at home. A report by Research and Markets predicts sales of these devices to reach $30 billion by 2023, up from $4.5 billion in 2017. In many ways, the medtech industry is playing catch-up with consumer technology. The stakes are high, and getting the user experience right is critical. 

AGENDA

4:00 PM - Registration & Networking

4:30 PM - Welcome & Panel Introductions 

4:35 PM - Panel Discussion

5:15 PM - Audience Q&A

5:30 PM - Networking Reception

DETAILS

Date: Thursday, January 30

Time: 4:00 - 6:00 PM

Location:

Map this event »
Life Science Washington - Conference Center
188 East Blaine Street
Seattle, Washington  98102

Panelists

Christine Farmer

Vice President & Site Head, Novo Nordisk Research Center Seattle, Inc.

CHRISTINE FARMER is the Vice President & Site Head of Novo Nordisk Research Center Seattle, Inc. In this role, Christine is responsible for developing and overseeing the strategic operations of the Novo Nordisk North American research centers with sites in Seattle, Boston, Indianapolis and Fremont, California. Prior to joining the R&D organization, Christine was Vice President, Commercial Operations at Novo Nordisk, Inc., where she had responsibilities that included the build-out of the company’s Digital Health & Innovation team. She has worked within the life sciences industry for 18 years and has held positions within marketing and sales both domestically and globally. Christine is extremely passionate about developing innovative business solutions designed to accelerate and amplify corporate growth strategies

Chris Rivera

Chairman, President and Chief Executive Officer, EMulate Therapeutics, Inc.

Chris Rivera has spent more than 30 years in numerous leadership roles in the biotechnology industry, including Chaiman, CEO and President of EMulate Therapeutics.  Prior to EMulate, Mr. Rivera was the founder and CEO of Hyperion Therapeutics, which was acquired by Horizon Pharma in 2015, Senior Vice President and head of Commercial Operations at Tercica, where he led the cross-licensing transaction between Tercica and Ipsen, and SVP at Genzyme Therapeutics, where he built and ran Genzyme’s US renal Commercial Operations, and helped launch Genzyme’s renal division globally. Prior to Genzyme, he helped build Cephalon and Centocor’s commercial infrastructures. 

He has also been recognized as a state and national leader through his appointments as; co-Chair for the Governor’s life science and global health advisory committee, Governor’s Higher Education Task Force, the Washington Global Health Funding Commission, and Chairman for the national Council of State Bioscience Associations.

Jeff LeBrun

Co-founder and CEO, optimize.health

Jeff LeBrun is the co-founder and CEO of optimize.health, a modern Remote Patient Monitoring (RPM) and Remote Care platform for healthcare providers. optimize.health spun out of a venture called Pillsy, a next-generation medication management platform that includes turnkey software and electronics for connected medication packaging. Over the past 10+ years, Jeff has been a co-founder or very early employee of several venture capital-backed startups with exits. Prior to Pillsy/optimize he co-founded Algal Scientific, which developed and commercialized a novel, orally-active immune-activating compound, and was the first business employee at Sakti3, which developed software and algorithms for battery design optimization. Jeff has also consulted for venture capital investors and for other startups. He holds a BS in biology with honors from the University of Puget Sound as well as MBA and MS degrees from the University of Michigan, where he was named a “Top 20” Alumni Entrepreneur by the business school.

Michael Hite

Co-founder and CEO, Parachute Therapeutics

Michael Hite is the co-founder and CEO of Parachute Therapeutics, a medical device company developing the Naloxone Parachute, a wearable device to detect and prevent fatal overdose from opioids.  The Naloxone Parachute uses multimodal biosensors to monitor patient vital signs and in the event of an overdose, autonomously deliver a rescue dose of naloxone (Narcan®) and contact help.  Michael is a 20 year veteran in pharmaceutical drug delivery and has co-invented and developed multiple technology platforms for oral, nasal and injectable therapeutics.  Prior to Parachute, Michael was the co-founder and CEO of Impel NeuroPharma.  Impel is using novel drug delivery and formulation science to develop transformative therapies for people suffering from central nervous system (CNS) disorders with high unmet medical needs, including acute migraine, and CNS complications from Parkinson’s disease, schizophrenia and bipolar disorder.  Michael holds a BA in Russian Studies from Amherst College and an MBA from the University of Washington.

Scott Thielman

Chief Technology Officer, Product Creation Studio

Scott Thielman is CTO and co-founder of Product Creation Studio. With expertise leading the development of consumer, medical and industrial products, Scott has participated in all aspects of development for clients including Philips, Johnson & Johnson, and Lilly. He holds a Ph.D. in mechanical engineering from the University of Washington and is a licensed professional engineer.